| 2.1384 0.108 (5.34%) | 10-15 12:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.55 | 1-year : | 2.98 |
| Resists | First : | 2.19 | Second : | 2.55 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.93 | Second : | 1.76 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 1.93 |
| MA(100) : | 2  |
MA(250) : | 1.96 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.2 |
D(3) : | 72.3 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 3.51 | Low : | 1.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IPHA ] has closed below upper band by 8.7%. Bollinger Bands are 11.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.17 | 2.17 - 2.18 |
| Low: | 2 - 2.01 | 2.01 - 2.02 |
| Close: | 2.01 - 2.03 | 2.03 - 2.05 |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Tue, 14 Oct 2025
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 - Business Wire
Tue, 23 Sep 2025
Innate Pharma (NASDAQ:IPHA) Cut to "Hold" at Leerink Partnrs - MarketBeat
Mon, 22 Sep 2025
Leerink Partners Reiterates "Market Perform" Rating for Innate Pharma (NASDAQ:IPHA) - MarketBeat
Thu, 18 Sep 2025
IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Ta - GuruFocus
Thu, 18 Sep 2025
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Thu, 18 Sep 2025
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | -523.2 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -271.4 % |
| Qtrly Rev. Growth | -60.6 % |
| Gross Profit (p.s.) | -0.34 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -3.32 |
| PEG Ratio | 0 |
| Price to Book value | 35.33 |
| Price to Sales | 15.45 |
| Price to Cash Flow | -4.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|